Abstract
Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy.
Original language | English |
---|---|
Pages (from-to) | 197-210 |
Journal | Clinical & Experimental Metastasis |
Volume | 33 |
Issue number | 2 |
Early online date | 30 Nov 2015 |
DOIs | |
Publication status | Published - Feb 2016 |
Keywords
- Angiogenesis
- Anti-angiogenesis
- Cancer
- Tumour
- Therapy